Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research.

Erice O, Vallejo A, Ponz-Sarvise M, Saborowski M, Vogel A, Calvisi DF, Saborowski A, Vicent S.

Cancers (Basel). 2019 Nov 26;11(12). pii: E1868. doi: 10.3390/cancers11121868. Review.

2.

Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.

Ponz-Sarvise M, Corbo V, Tiriac H, Engle DD, Frese KK, Oni TE, Hwang CI, Öhlund D, Chio IIC, Baker LA, Filippini D, Wright K, Bapiro TE, Huang P, Smith P, Yu KH, Jodrell DI, Park Y, Tuveson DA.

Clin Cancer Res. 2019 Nov 15;25(22):6742-6755. doi: 10.1158/1078-0432.CCR-19-1398. Epub 2019 Sep 6.

PMID:
31492749
3.

Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack.

Salas-Benito D, Melero I, Ponz-Sarvise M.

Clin Cancer Res. 2019 Sep 15;25(18):5435-5437. doi: 10.1158/1078-0432.CCR-19-1753. Epub 2019 Jul 17.

PMID:
31315885
4.

Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse.

Sala Elarre P, Oyaga-Iriarte E, Yu KH, Baudin V, Arbea Moreno L, Carranza O, Chopitea Ortega A, Ponz-Sarvise M, Mejías Sosa LD, Rotellar Sastre F, Larrea Leoz B, Iragorri Barberena Y, Subtil Iñigo JC, Benito Boíllos A, Pardo F, Rodríguez Rodríguez J.

Cancers (Basel). 2019 Apr 30;11(5). pii: E606. doi: 10.3390/cancers11050606.

5.

Clinical presentation, diagnosis and staging of cholangiocarcinoma.

Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A.

Liver Int. 2019 May;39 Suppl 1:98-107. doi: 10.1111/liv.14086. Epub 2019 Mar 25. Review.

PMID:
30831002
6.

TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.

Rodríguez-Ruiz ME, Rodríguez I, Mayorga L, Labiano T, Barbes B, Etxeberria I, Ponz-Sarvise M, Azpilikueta A, Bolaños E, Sanmamed MF, Berraondo P, Calvo FA, Barcelos-Hoff MH, Perez-Gracia JL, Melero I.

Mol Cancer Ther. 2019 Mar;18(3):621-631. doi: 10.1158/1535-7163.MCT-18-0558. Epub 2019 Jan 25.

PMID:
30683810
7.

Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Baraibar I, Melero I, Ponz-Sarvise M, Castanon E.

Drug Saf. 2019 Feb;42(2):281-294. doi: 10.1007/s40264-018-0774-8. Review.

PMID:
30649742
8.

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.

Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I.

Cancer Res. 2019 Feb 1;79(3):625-638. doi: 10.1158/0008-5472.CAN-18-1479. Epub 2018 Dec 18.

PMID:
30563891
9.

Cytokines in clinical cancer immunotherapy.

Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I.

Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Review.

10.

A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis.

Rodriguez J, Castañón E, Perez-Gracia JL, Rodriguez I, Viudez A, Alfaro C, Oñate C, Perez G, Rotellar F, Inogés S, López-Diaz de Cerio A, Resano L, Ponz-Sarvise M, Rodriguez-Ruiz ME, Chopitea A, Vera R, Melero I.

J Immunother Cancer. 2018 Sep 29;6(1):96. doi: 10.1186/s40425-018-0405-z.

11.

Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center.

Rodriguez J, Vicent S, Chopitea A, Ponz-Sarvisé M.

Clin Cancer Res. 2018 Aug 15;24(16):3787-3789. doi: 10.1158/1078-0432.CCR-18-0818. Epub 2018 Apr 20.

12.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.

Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089.

PMID:
29554212
13.

Revisiting Interleukin-12 as a Cancer Immunotherapy Agent.

Berraondo P, Etxeberria I, Ponz-Sarvise M, Melero I.

Clin Cancer Res. 2018 Jun 15;24(12):2716-2718. doi: 10.1158/1078-0432.CCR-18-0381. Epub 2018 Mar 16.

14.

Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies.

Rodriguez-Ruiz ME, Rodriguez I, Barbes B, Mayorga L, Sanchez-Paulete AR, Ponz-Sarvise M, Pérez-Gracia JL, Melero I.

Brachytherapy. 2017 Nov - Dec;16(6):1246-1251. doi: 10.1016/j.brachy.2017.06.012. Epub 2017 Aug 21.

PMID:
28838649
15.

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA.

J Exp Med. 2017 Mar 6;214(3):579-596. doi: 10.1084/jem.20162024. Epub 2017 Feb 23.

16.

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.

Vallejo A, Perurena N, Guruceaga E, Mazur PK, Martinez-Canarias S, Zandueta C, Valencia K, Arricibita A, Gwinn D, Sayles LC, Chuang CH, Guembe L, Bailey P, Chang DK, Biankin A, Ponz-Sarvise M, Andersen JB, Khatri P, Bozec A, Sweet-Cordero EA, Sage J, Lecanda F, Vicent S.

Nat Commun. 2017 Feb 21;8:14294. doi: 10.1038/ncomms14294.

17.

Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.

Martin-Romano P, Sola JJ, Diaz-Gonzalez JA, Chopitea A, Iragorri Y, Martínez-Regueira F, Ponz-Sarvise M, Arbea L, Subtil JC, Cano D, Ceniceros L, Legaspi J, Hernandez JL, Rodríguez J.

Br J Cancer. 2016 Sep 6;115(6):655-63. doi: 10.1038/bjc.2016.252. Epub 2016 Aug 18.

18.

NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer.

Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Wilson J, Sangar V, Hao Y, Öhlund D, Wright K, Filippini D, Lee EJ, Da Silva B, Schoepfer C, Wilkinson JE, Buscaglia JM, DeNicola GM, Tiriac H, Hammell M, Crawford HC, Schmidt EE, Thompson CB, Pappin DJ, Sonenberg N, Tuveson DA.

Cell. 2016 Aug 11;166(4):963-976. doi: 10.1016/j.cell.2016.06.056. Epub 2016 Jul 28.

19.

Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing.

Teijeira A, Etxeberria I, Ponz-Sarvise M, Melero I.

Clin Cancer Res. 2016 Sep 1;22(17):4277-9. doi: 10.1158/1078-0432.CCR-16-1072. Epub 2016 Jun 21.

20.

Mouse Models of Pancreatic Ductal Adenocarcinoma.

Ponz-Sarvise M, Tuveson DA, Yu KH.

Hematol Oncol Clin North Am. 2015 Aug;29(4):609-17. doi: 10.1016/j.hoc.2015.04.010. Epub 2015 Jun 11. Review.

PMID:
26226900
21.

Proteasome inhibition enhances the killing effect of BikDD gene therapy.

Sun Y, Ponz-Sarvise M, Chang SS, Chang WC, Chen CH, Hsu JL, Hung MC.

Am J Transl Res. 2015 Feb 15;7(2):319-27. eCollection 2015.

22.

Organoid models of human and mouse ductal pancreatic cancer.

Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA.

Cell. 2015 Jan 15;160(1-2):324-38. doi: 10.1016/j.cell.2014.12.021. Epub 2014 Dec 31.

23.

The RAS and YAP1 dance, who is leading?

Corbo V, Ponz-Sarvise M, Tuveson DA.

EMBO J. 2014 Nov 3;33(21):2437-8. doi: 10.15252/embj.201490014. Epub 2014 Sep 25. No abstract available.

24.

S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer.

Khotskaya YB, Goverdhan A, Shen J, Ponz-Sarvise M, Chang SS, Hsu MC, Wei Y, Xia W, Yu D, Hung MC.

Am J Transl Res. 2014 Jul 18;6(4):361-76. eCollection 2014.

25.

Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications.

Ponz-Sarvisé M, Castañón E, Panizo-Santos A, Redrado M, López I, Rosell D, Gil-Aldea I, Calvo A, Nguewa PA, Gil-Bazo I.

Clin Genitourin Cancer. 2014 Apr;12(2):87-93. doi: 10.1016/j.clgc.2013.08.007. Epub 2013 Oct 12.

PMID:
24129125
26.

Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.

Ponz-Sarvisé M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, Pio R, Behrens C, Wistuba II, García-Franco CE, García-Foncillas J, Montuenga LM, Calvo A, Gil-Bazo I.

Clin Cancer Res. 2011 Jun 15;17(12):4155-66. doi: 10.1158/1078-0432.CCR-10-3381. Epub 2011 May 3.

27.

Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy.

Rodriguez J, Boni V, Hernández A, Bitarte N, Zarate R, Ponz-Sarvisé M, Chopitea A, Bandres E, Garcia-Foncillas J.

Eur J Cancer. 2011 Apr;47(6):839-47. doi: 10.1016/j.ejca.2010.11.032. Epub 2011 Jan 8.

PMID:
21220199
28.

TGFBI expression is associated with a better response to chemotherapy in NSCLC.

Irigoyen M, Pajares MJ, Agorreta J, Ponz-Sarvisé M, Salvo E, Lozano MD, Pío R, Gil-Bazo I, Rouzaut A.

Mol Cancer. 2010 May 28;9:130. doi: 10.1186/1476-4598-9-130.

29.

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.

Zarate R, Rodríguez J, Bandres E, Patiño-Garcia A, Ponz-Sarvise M, Viudez A, Ramirez N, Bitarte N, Chopitea A, Gacía-Foncillas J.

Br J Cancer. 2010 Mar 16;102(6):987-94. doi: 10.1038/sj.bjc.6605595. Epub 2010 Mar 9.

30.

Id-1 expression and prognosis in cancer: do antibodies matter?

Gil-Bazo I, Ponz-Sarvisé M, Panizo-Santos A, Calvo A.

Clin Transl Oncol. 2010 Jan;12(1):69. doi: 10.1007/s12094-010-0470-3. No abstract available.

PMID:
20080475
31.

Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab.

Rodríguez J, Viúdez A, Ponz-Sarvisé M, Gil-Aldea I, Chopitea A, García-Foncillas J, Gil-Bazo I.

Crit Rev Oncol Hematol. 2010 Jun;74(3):193-202. doi: 10.1016/j.critrevonc.2009.07.005. Epub 2009 Aug 22. Review.

PMID:
19700342
32.

Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).

García-Muñoz R, Galar A, Moreno C, Rodríguez-Otero P, Panizo-Morgado E, Ponz-Sarvisê M, Fernandez-Alonso M, Rubio M, Merino J, Cuesta B, Panizol C, Prosper F.

Leuk Lymphoma. 2007 Dec;48(12):2461-4. No abstract available.

PMID:
18067026
33.

Acquired nasopharyngeal stenosis: surgical treatment for this unusual complication after chemoradiation for nasopharyngeal carcinoma.

Baptista P, Carlos GV, Salvinelli F, Ponz-Sarvise M, Casale M.

Otolaryngol Head Neck Surg. 2007 Dec;137(6):959-61. No abstract available. Erratum in: Otolaryngol Head Neck Surg. 2008 Jan;138(1):127. Carlos, Gimenone-Vilar [corrected to Carlos, Gimeno-Vilar]; Ponz-Sarvise, Marianone [corrected to Ponz-Sarvise, Mariano].

PMID:
18036430
34.

Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?

Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, Gil-Bazo I.

World J Gastroenterol. 2007 Nov 28;13(44):5877-87. Review.

Supplemental Content

Loading ...
Support Center